Interrelationship between chronic kidney disease and risk of cardiovascular diseases

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2013, Pages 38-43

  Hernandez, German T ^a   Sippel, Michael ^a   Mukherjee, Debabrata ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Acute coronary syndrome; Anemia; Cardiovascular disease; Chronic kidney disease; Dialysis; Dyslipidemia; Glomerular filtration rate; Hypertension; Outcomes; Secondary prevention; Uremia

Indexed keywords

HOMOCYSTEINE; PHOSPHATE;

ALBUMINURIA; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; MORBIDITY; NONHUMAN; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SMOKING; UREMIA;

CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84873168480     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/1871525711311010007     Document Type: Article

References (67)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 2002, 39(2 Suppl. 1), S1-266.
2. US Renal Data System. USRDS 1998 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 1998. http://www.usrds.org/download/1998/begin.pdf [Accessed on 7th June 2012].
3. Jones, C.A.; McQuillan, G.M.; Kusek, J.W.; Eberhardt, M.S.; Herman, W.H.; Coresh, J.; Salive, M.; Jones, C.P.; Agodoa, L.Y. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am. J. Kidney Dis., 1998, 32(6), 992-999.
4. Summaries for patients. Diagnosis and evaluation of patients with chronic kidney disease: recommendations from the National Kidney Foundation. Ann. Intern. Med., 2003, 139(2), I36.
5. Di Angelantonio, E.; Chowdhury, R.; Sarwar, N.; Aspelund, T.; Danesh, J.; Gudnason, V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ, 2010, 341, c4986.
6. Manjunath, G.; Tighiouart, H.; Ibrahim, H.; MacLeod, B.; Salem, D.N.; Griffith, J.L.; Coresh, J.; Levey, A.S.; Sarnak, M.J. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J. Am. Coll. Cardiol., 2003, 41(1), 47-55.
7. Standards of medical care in diabetes--2010. Diabetes Care, 2010, 33(Suppl. 1), S11-61.
8. Weiner, D.E.; Tighiouart, H.; Amin, M.G.; Stark, P.C.; MacLeod, B.; Griffith, J.L.; Salem, D.N.; Levey, A.S.; Sarnak, M.J. Chronic kidney disease as a risk factor for cardiovascular disease and allcause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol., 2004, 15(5), 1307-1315.
9. Muntner, P.; He, J.; Hamm, L.; Loria, C.; Whelton, P.K. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol., 2002, 13(3), 745-753.
10. Sarnak, M.J.; Coronado, B.E.; Greene, T.; Wang, S.R.; Kusek, J.W.; Beck, G.J.; Levey, A.S. Cardiovascular disease risk factors in chronic renal insufficiency. Clin. Nephrol., 2002, 57(5), 327-335.
11. Coresh, J.; Astor, B.C.; Greene, T.; Eknoyan, G.; Levey, A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis., 2003, 41(1), 1-12.
12. Garg, A.X.; Clark, W.F.; Haynes, R.B.; House, A.A. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int., 2002, 61(4), 1486-1494.
13. Culleton, B.F.; Hemmelgarn, B.R. Is chronic kidney disease a cardiovascular disease risk factor? Semin. Dial., 2003, 16(2), 95-100.
14. Herzog, C.A.; Ma, J.Z.; Collins, A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N. Engl. J. Med., 1998, 339(12), 799-805.
15. Gibson, C.M.; Dumaine, R.L.; Gelfand, E.V.; Murphy, S.A.; Morrow, D.A.; Wiviott, S.D.; Giugliano, R.P.; Cannon, C.P.; Antman, E.M.; Braunwald, E. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur. Heart J., 2004, 25(22), 1998-2005.
16. Wright, R.S.; Reeder, G.S.; Herzog, C.A.; Albright, R.C.; Williams, B.A.; Dvorak, D.L.; Miller, W.L.; Murphy, J.G.; Kopecky, S.L.; Jaffe, A.S. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med., 2002, 137(7), 563-570.
17. Anavekar, N.S.; McMurray, J.J.; Velazquez, E.J.; Solomon, S.D.; Kober, L.; Rouleau, J.L.; White, H.D.; Nordlander, R.; Maggioni, A.; Dickstein, K.; Zelenkofske, S.; Leimberger, J.D.; Califf, R.M.; Pfeffer, M.A. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med., 2004, 351(13), 1285-1295.
18. Shlipak, M.G.; Heidenreich, P.A.; Noguchi, H.; Chertow, G.M.; Browner, W.S.; McClellan, M.B. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann. Intern. Med., 2002, 137(7), 555-562.
19. Gibson, C.M.; Pinto, D.S.; Murphy, S.A.; Morrow, D.A.; Hobbach, H.P.; Wiviott, S.D.; Giugliano, R.P.; Cannon, C.P.; Antman, E.M.; Braunwald, E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J. Am. Coll. Cardiol., 2003, 42(9), 1535-1543.
20. Harada, R.K.; Eagle, K.A.; Kline-Rogers, E.M.; Fang, J.; Smith, D.; Mukherjee, D. Low utilization of secondary preventive medications and its potential impact in patients with chronic kidney disease and acute coronary syndromes. Indian Heart J., 2006, 58(3), 222-229.
21. Foley, R.N.; Parfrey, P.S.; Sarnak, M.J. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol., 1998, 9(12 Suppl), S16-23.
22. Januzzi, J.L., Jr.; Snapinn, S.M.; DiBattiste, P.M.; Jang, I.K.; Theroux, P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation, 2002, 105(20), 2361-2366.
23. Mailloux, L.U. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin. Nephrol., 2001, 21(2), 146-156.
24. Kasiske, B.L. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis., 1998, 32(5 Suppl. 3), S142-156.
25. Tschope, W.; Koch, M.; Thomas, B.; Ritz, E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron., 1993, 64(3), 354-358.
26. Cressman, M.D.; Heyka, R.J.; Paganini, E.P.; O'Neil, J.; Skibinski, C.I.; Hoff, H.F. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation, 1992, 86(2), 475-482.
27. Strippoli, G.F.; Navaneethan, S.D.; Johnson, D.W.; Perkovic, V.; Pellegrini, F.; Nicolucci, A.; Craig, J.C. Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomised controlled trials. BMJ, 2008, 336(7645), 645-651.
28. Fellstrom, B.C.; Jardine, A.G.; Schmieder, R.E.; Holdaas, H.; Bannister, K.; Beutler, J.; Chae, D.W.; Chevaile, A.; Cobbe, S.M.; Gronhagen-Riska, C.; De Lima, J.J.; Lins, R.; Mayer, G.; McMahon, A.W.; Parving, H.H.; Remuzzi, G.; Samuelsson, O.; Sonkodi, S.; Sci, D.; Suleymanlar, G.; Tsakiris, D.; Tesar, V.; Todorov, V.; Wiecek, A.; Wuthrich, R.P.; Gottlow, M.; Johnsson, E.; Zannad, F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med., 2009, 360(14), 1395-1407.
29. Wanner, C.; Krane, V.; Marz, W.; Olschewski, M.; Mann, J.F.; Ruf, G.; Ritz, E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med., 2005, 353(3), 238-248.
30. Baigent, C.; Landray, M.J.; Reith, C.; Emberson, J.; Wheeler, D.C.; Tomson, C.; Wanner, C.; Krane, V.; Cass, A.; Craig, J.; Neal, B.; Jiang, L.; Hooi, L.S.; Levin, A.; Agodoa, L.; Gaziano, M.; Kasiske, B.; Walker, R.; Massy, Z.A.; Feldt-Rasmussen, B.; Krairittichai, U.; Ophascharoensuk, V.; Fellstrom, B.; Holdaas, H.; Tesar, V.; Wiecek, A.; Grobbee, D.; de Zeeuw, D.; Gronhagen-Riska, C.; Dasgupta, T.; Lewis, D.; Herrington, W.; Mafham, M.; Majoni, W.; Wallendszus, K.; Grimm, R.; Pedersen, T.; Tobert, J.; Armitage, J.; Baxter, A.; Bray, C.; Chen, Y.; Chen, Z.; Hill, M.; Knott, C.; Parish, S.; Simpson, D.; Sleight, P.; Young, A.; Collins, R. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011, 377(9784), 2181-2192.
31. Pyram, R.; Kansara, A.; Banerji, M.A.; Loney-Hutchinson, L. Chronic kidney disease and diabetes. Maturitas, 2012, 71(2), 94-103.
32. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352(9131), 837-853.
33. Alwakeel, J.S.; Isnani, A.C.; Alsuwaida, A.; Alharbi, A.; Shaffi, S.A.; Almohaya, S.; Al Ghonaim, M. Factors affecting the progression of diabetic nephropathy and its complications: a singlecenter experience in Saudi Arabia. Ann. Saudi Med., 2011, 31(3), 236-242.
34. Goldschmid, M.G.; Domin, W.S.; Ziemer, D.C.; Gallina, D.L.; Phillips, L.S. Diabetes in urban African-Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care, 1995, 18(7), 955-961.
35. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am. J. Kidney Dis., 2007, 49(2 Suppl. 2), S12-154.
36. Orth, S.R.; Ritz, E. The renal risks of smoking: an update. Curr. Opin. Nephrol. Hypertens., 2002, 11(5), 483-488.
37. Stack, A.G.; Bloembergen, W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J. Am. Soc. Nephrol., 2001, 12(7), 1516-1523.
38. Albert, M.A.; Glynn, R.J.; Ridker, P.M. Plasma concentration of Creactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation, 2003, 108(2), 161-165.
39. Al Suwaidi, J.; Reddan, D.N.; Williams, K.; Pieper, K.S.; Harrington, R.A.; Califf, R.M.; Granger, C.B.; Ohman, E.M.; Holmes, D.R., Jr. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation, 2002, 106(8), 974-980.
40. Keeley, E.C.; Kadakia, R.; Soman, S.; Borzak, S.; McCullough, P.A. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am. J. Cardiol., 2003, 92(5), 509-514.
41. Oberg, B.P.; McMenamin, E.; Lucas, F.L.; McMonagle, E.; Morrow, J.; Ikizler, T.A.; Himmelfarb, J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int., 2004, 65(3), 1009-1016.
42. Miyata, T.; Sugiyama, S.; Saito, A.; Kurokawa, K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int. Suppl., 2001, 78, S25-31.
43. Menon, V.; Wang, X.; Greene, T.; Beck, G.J.; Kusek, J.W.; Marcovina, S.M.; Levey, A.S.; Sarnak, M.J. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am. J. Kidney Dis., 2003, 42(1), 44-52.
44. Iseki, K.; Tozawa, M.; Yoshi, S.; Fukiyama, K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol. Dial. Transplant., 1999, 14(8), 1956-1960.
45. Ridker, P.M.; Stampfer, M.J.; Rifai, N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001, 285(19), 2481-2485.
46. Hegarty, J.; Foley, R.N. Anaemia, renal insufficiency and cardiovascular outcome. Nephrol Dial Transplant., 2001, 16(Suppl. 1), 102-104.
47. Borch-Johnsen, K.; Feldt-Rasmussen, B.; Strandgaard, S.; Schroll, M.; Jensen, J.S. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler. Thromb. Vasc. Biol., 1999, 19(8), 1992-1997.
48. Deckert, T.; Kofoed-Enevoldsen, A.; Norgaard, K.; Borch-Johnsen, K.; Feldt-Rasmussen, B.; Jensen, T. Microalbuminuria. Implications for micro-and macrovascular disease. Diabetes Care, 1992, 15(9), 1181-1191.
49. Hillege, H.L.; Fidler, V.; Diercks, G.F.; van Gilst, W.H.; de Zeeuw, D.; van Veldhuisen, D.J.; Gans, R.O.; Janssen, W.M.; Grobbee, D.E.; de Jong, P.E. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation, 2002, 106(14), 1777-1782.
50. Gerstein, H.C.; Mann, J.F.; Yi, Q.; Zinman, B.; Dinneen, S.F.; Hoogwerf, B.; Halle, J.P.; Young, J.; Rashkow, A.; Joyce, C.; Nawaz, S.; Yusuf, S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 2001, 286(4), 421-426.
51. Friedman, A.N.; Bostom, A.G.; Selhub, J.; Levey, A.S.; Rosenberg, I.H. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol., 2001, 12(10), 2181-2189.
52. Luft, F.C. Renal disease as a risk factor for cardiovascular disease. Basic Res. Cardiol., 2000, 95(Suppl. 1), 172-176.
53. Hruska, K.; Mathew, S.; Lund, R.; Fang, Y.; Sugatani, T. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int. Suppl., 2011, (121), S9-13.
54. McCullough, P.A. Cardiorenal risk: an important clinical intersection. Rev. Cardiovasc. Med., 2002, 3(2), 71-76.
55. Berger, A.K.; Duval, S.; Krumholz, H.M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol., 2003, 42(2), 201-208.
56. Winkelmayer, W.C.; Charytan, D.M.; Levin, R.; Avorn, J. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am. J. Kidney Dis., 2006, 47(2), 301-308.
57. Zebrack, J.S.; Anderson, J.L.; Beddhu, S.; Horne, B.D.; Bair, T.L.; Cheung, A.; Muhlestein, J.B. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J. Am. Coll. Cardiol., 2003, 42(1), 57-63.
58. Austen, S.K.; Coombes, J.S.; Fassett, R.G. Homocysteine and cardiovascular disease in renal disease. Nephrology (Carlton), 2003, 8(6), 285-295.
59. Kaysen, G.A.; Eiserich, J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J. Am. Soc. Nephrol., 2004, 15(3), 538-548.
60. Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992, 339(8793), 572-575.
61. Kielstein, J.T.; Boger, R.H.; Bode-Boger, S.M.; Frolich, J.C.; Haller, H.; Ritz, E.; Fliser, D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol., 2002, 13(1), 170-176.
62. Zoccali, C.; Mallamaci, F.; Tripepi, G. Novel cardiovascular risk factors in end-stage renal disease. J. Am. Soc. Nephrol., 2004, 15(Suppl. 1), S77-80.
63. McCullough, P.A.; Sandberg, K.R.; Dumler, F.; Yanez, J.E. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J. Nephrol., 2004, 17(2), 205-215.
64. Stevens, L.A.; Levin, A. Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. Curr. Opin. Nephrol. Hypertens., 2003, 12(2), 133-138.
65. Levin, A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int. Suppl., 2002, (80), 35-38.
66. Anavekar, N.S.; Pfeffer, M.A. Cardiovascular risk in chronic kidney disease. Kidney Int. Suppl., 2004, 66(92), S11-15.
67. Parfrey, P.S.; Foley, R.N. The clinical epidemiology of cardiac disease in chronic renal failure. J. Am. Soc. Nephrol., 1999, 10(7), 1606-1615.